 SAN FRANCISCO, April 13, 2020 GLOBE NEWSWIRE -- 89bio, Inc. ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it closed enrollment in its Phase 1b2a trial for nonalcoholic steatohepatitis NASH with 98 of patients enrolled and has delayed initiation of its severe hypertriglyceridemia SHTG trial due to the ongoing COVID-19 pandemic. 89bio also reported new preclinical data confirming BIO89-100s mechanism of action via potent FGF receptor agonism. 